- The approval is based on P-III IKEMA study assessing Sarclisa in combination with carfilzomib and dexamethasone (Kd) in 302 patients with relapsed MM who have received 1 to 3 prior lines of therapy across 69 centers spanning 16 countries
- The addition of Kd in Sarclisa leads to a 47% reduction in the risk of disease progression and death, and the benefit was evident across all patient subgroups
- The approval marks the second indication for the Sarclisa combination regimen for RRMM. Previously, Sarclisa received Health Canada approval in combination with Pd for patients with RRMM who have received at least two prior therapies including lenalidomide and a proteasome inhibitor
Click here to read full press release/ article | Ref: Newswire.Ca | Image: Evaluate Pharma
The post Sanofi’s Sarclisa Combination Regimen Receives Health Canada’s Approval for Multiple Myeloma first appeared on PharmaShots.